[go: up one dir, main page]

LT2536399T - Biomolekulių aktyvinimo ir konjugavimo būdas - Google Patents

Biomolekulių aktyvinimo ir konjugavimo būdas

Info

Publication number
LT2536399T
LT2536399T LTEP11745404.1T LT11745404T LT2536399T LT 2536399 T LT2536399 T LT 2536399T LT 11745404 T LT11745404 T LT 11745404T LT 2536399 T LT2536399 T LT 2536399T
Authority
LT
Lithuania
Prior art keywords
biomolecules
conjugation
activation
Prior art date
Application number
LTEP11745404.1T
Other languages
English (en)
Inventor
Jens H. Vogel
Chi Shung Brian To
Carolina Lucia Bianco
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of LT2536399T publication Critical patent/LT2536399T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/025Reverse osmosis; Hyperfiltration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2315/00Details relating to the membrane module operation
    • B01D2315/10Cross-flow filtration
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2315/00Details relating to the membrane module operation
    • B01D2315/16Diafiltration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Water Supply & Treatment (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
LTEP11745404.1T 2010-02-21 2011-02-21 Biomolekulių aktyvinimo ir konjugavimo būdas LT2536399T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30651310P 2010-02-21 2010-02-21
PCT/US2011/025592 WO2011103531A1 (en) 2010-02-21 2011-02-21 Method for Activation and Conjugation of Biomolecules

Publications (1)

Publication Number Publication Date
LT2536399T true LT2536399T (lt) 2020-03-10

Family

ID=44483343

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11745404.1T LT2536399T (lt) 2010-02-21 2011-02-21 Biomolekulių aktyvinimo ir konjugavimo būdas

Country Status (34)

Country Link
US (1) US9254336B2 (lt)
EP (1) EP2536399B1 (lt)
JP (1) JP5726915B2 (lt)
KR (1) KR101776976B1 (lt)
CN (2) CN102970988B (lt)
AU (1) AU2011217794B2 (lt)
BR (1) BR112012020855B8 (lt)
CA (1) CA2790401C (lt)
CL (1) CL2012002306A1 (lt)
CO (1) CO6592111A2 (lt)
CR (1) CR20120437A (lt)
CU (1) CU20120121A7 (lt)
CY (1) CY1122711T1 (lt)
DK (1) DK2536399T3 (lt)
EA (1) EA201290804A1 (lt)
EC (1) ECSP12012112A (lt)
ES (1) ES2769629T3 (lt)
GT (1) GT201200244A (lt)
HR (1) HRP20192164T1 (lt)
HU (1) HUE047661T2 (lt)
IL (1) IL221447A (lt)
LT (1) LT2536399T (lt)
MX (1) MX2012009674A (lt)
NZ (1) NZ601905A (lt)
PE (1) PE20130003A1 (lt)
PH (2) PH12012501664A1 (lt)
PL (1) PL2536399T3 (lt)
PT (1) PT2536399T (lt)
RS (1) RS59827B1 (lt)
SG (1) SG183309A1 (lt)
SI (1) SI2536399T1 (lt)
UA (1) UA115221C2 (lt)
WO (1) WO2011103531A1 (lt)
ZA (2) ZA201206215B (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE481323A (lt) * 1947-04-10
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
WO2015089449A2 (en) 2013-12-12 2015-06-18 Stem Centrx, Inc. Novel anti-dpep3 antibodies and methods of use
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗mfi2抗體及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384909B2 (en) * 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
ATE491725T1 (de) * 2002-07-15 2011-01-15 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
AU2003300139B2 (en) 2002-12-31 2008-08-28 Nektar Therapeutics Maleamic acid polymer derivatives and their bioconjugates
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
LT1824988T (lt) * 2004-11-12 2017-10-25 Bayer Healthcare Llc Nukreipta į užduotą saitą fviii modifikacija
US20070173634A1 (en) * 2006-01-24 2007-07-26 Olsson Nils U Methods for one-step purification of organic polymers using tangential flow filtration
US20080220448A1 (en) * 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
US8207298B2 (en) 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
SG178141A1 (en) * 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
CN107412754A (zh) * 2009-12-22 2017-12-01 塞尔德克斯医疗公司 疫苗组合物

Also Published As

Publication number Publication date
CO6592111A2 (es) 2013-01-02
CN105664175A (zh) 2016-06-15
CU20120121A7 (es) 2013-01-30
AU2011217794A1 (en) 2012-09-20
CA2790401A1 (en) 2011-08-25
NZ601905A (en) 2014-09-26
EP2536399A4 (en) 2016-02-24
JP5726915B2 (ja) 2015-06-03
CL2012002306A1 (es) 2013-01-18
BR112012020855B1 (pt) 2021-05-04
CY1122711T1 (el) 2021-03-12
KR20120120966A (ko) 2012-11-02
CR20120437A (es) 2012-12-07
EP2536399B1 (en) 2019-11-20
ZA201405941B (en) 2018-05-31
SI2536399T1 (sl) 2020-02-28
CN102970988B (zh) 2016-03-16
BR112012020855A2 (pt) 2017-08-29
HRP20192164T1 (hr) 2020-03-06
US9254336B2 (en) 2016-02-09
BR112012020855B8 (pt) 2021-05-25
RS59827B1 (sr) 2020-02-28
EA201290804A1 (ru) 2013-03-29
EP2536399A1 (en) 2012-12-26
US20130040362A1 (en) 2013-02-14
SG183309A1 (en) 2012-09-27
DK2536399T3 (da) 2020-02-10
PH12016501602A1 (en) 2017-06-05
HK1182330A1 (zh) 2013-11-29
IL221447A0 (en) 2012-10-31
CN105664175B (zh) 2019-07-23
HK1225652A1 (zh) 2017-09-15
PE20130003A1 (es) 2013-01-19
ECSP12012112A (es) 2012-10-30
ZA201206215B (en) 2014-10-29
MX2012009674A (es) 2012-09-07
HUE047661T2 (hu) 2020-05-28
WO2011103531A1 (en) 2011-08-25
JP2013520441A (ja) 2013-06-06
PH12012501664A1 (en) 2012-10-22
PL2536399T3 (pl) 2020-06-29
CN102970988A (zh) 2013-03-13
ES2769629T3 (es) 2020-06-26
KR101776976B1 (ko) 2017-09-08
PT2536399T (pt) 2020-02-06
IL221447A (en) 2015-09-24
UA115221C2 (uk) 2017-10-10
AU2011217794B2 (en) 2015-01-29
CA2790401C (en) 2018-05-29
GT201200244A (es) 2014-09-02

Similar Documents

Publication Publication Date Title
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
BR112012017441A2 (pt) compostos e métodos
EP2534178A4 (en) THERAPEUTIC PROCEDURES WITH TI-CD200 ANTIBODIES
BR112012015988A2 (pt) método
CR20130228A (es) Anticuerpos neutralizadores anti-ccl20
HUE056313T2 (hu) Anti-DLL3 antitest
DK3045187T3 (da) Injektor og fremgangsmåde til samling
BR112013001592A2 (pt) artigo e método
BR112013016969A2 (pt) aparelho e método
BR112013009489A2 (pt) aparelho e método de conexão
LT2794654T (lt) Anti-phf-tau antikūnai ir jų panaudojimas
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
PT3412687T (pt) Métodos de tratamento de dlbcl
BR112013010847A2 (pt) artigo e método
BR112012028015A2 (pt) aparelho e método
CO6791565A2 (es) Anticuerpos anti-notch1
DK2571624T3 (da) Multifysisk brændstofforstøver og fremgangsmåder
DK3275896T3 (da) Fremgangsmåde til at opnå antistoffer
BR112013016641A2 (pt) artigo e método
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
BR112013012751A2 (pt) aparelho complexo
DK2908661T3 (da) Mikroalgemelgranulater og fremgangsmåde til fremstilling deraf
EP2543670A4 (en) Pyrazolopyrimidine DERIVATIVE
BR112013009579A2 (pt) método e comprimido
BR112013011848A2 (pt) método de conexão melhorado